FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1542321037> ?p ?o ?g. }

• W1542321037 abstract "Aims Sildenafil, an effective oral treatment for erectile dysfunction, is predominantly metabolized by the cytochrome P450 isozyme 3A4, which is inhibited by a number of the macrolide antibiotics. Therefore, two placebo‐controlled, parallel‐group studies were conducted to evaluate the effects of multiple doses of erythromycin and azithromycin on the pharmacokinetics, safety and tolerability of a single oral 100‐mg dose of sildenafil. Methods In the erythromycin interaction study, 26 male volunteers (18–45 years of age) received open‐label sildenafil 100 mg on day 1. Half received blinded erythromycin (500 mg) twice daily on days 2–6, and the other half received placebo. On day 6, all subjects received a second 100‐mg dose of sildenafil. In the azithromycin interaction study, 24 male volunteers (19–33 years of age) received open‐label 100 mg sildenafil on day 1. Half then received blinded azithromycin (500 mg) once daily on days 2–4, and the other half received placebo. On day 4, all subjects received another 100‐mg dose of sildenafil. In both studies, blood samples were collected on the first and last study day for the analysis of plasma concentrations of sildenafil and its primary metabolite, UK‐103,320. Results Repeated dosing with erythromycin caused statistically significant increases in the AUC and C max of sildenafil (2.8‐fold and 2.6‐fold, respectively) but had no effect on T max , k el or t 1/2 . A statistically significant 1.4‐fold increase in the AUC of UK‐103,320 was also observed, as well as a significant decrease in k el , resulting in an increase of about 1 h in t 1/2 . In contrast, repeated dosing with azithromycin caused no significant change in any pharmacokinetic parameter of either sildenafil or UK‐103,320. Erythromycin, azithromycin and sildenafil were well tolerated; adverse events were mild and transient. No subject withdrew from either trial for any reason related to study drug. Conclusions These results indicate that erythromycin modifies the pharmacokinetics of sildenafil by inhibiting its CYP3A4‐mediated first‐pass metabolism. Given these data, a lower starting dose of sildenafil (25 mg) may be considered for patients receiving erythromycin or other potent CYP3A4 inhibitors. Azithromycin did not affect the pharmacokinetics of sildenafil; therefore, no adjustment in dosage is necessary for patients receiving these drugs concomitantly." @default.
• W1542321037 created "2016-06-24" @default.
• W1542321037 creator A5043906653 @default.
• W1542321037 creator A5056361445 @default.
• W1542321037 creator A5061029367 @default.
• W1542321037 creator A5083601745 @default.
• W1542321037 date "2002-02-01" @default.
• W1542321037 modified "2023-10-18" @default.
• W1542321037 title "The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers" @default.
• W1542321037 cites W1484324193 @default.
• W1542321037 cites W1556402834 @default.
• W1542321037 cites W1697899995 @default.
• W1542321037 cites W1956875558 @default.
• W1542321037 cites W1986119856 @default.
• W1542321037 cites W1990652438 @default.
• W1542321037 cites W2024587809 @default.
• W1542321037 cites W2027251910 @default.
• W1542321037 cites W2034331352 @default.
• W1542321037 cites W2044207900 @default.
• W1542321037 cites W2049076878 @default.
• W1542321037 cites W2092243607 @default.
• W1542321037 cites W2104093795 @default.
• W1542321037 cites W2108063153 @default.
• W1542321037 cites W2120917180 @default.
• W1542321037 cites W2147471852 @default.
• W1542321037 cites W2155268095 @default.
• W1542321037 cites W2158478351 @default.
• W1542321037 cites W2168038873 @default.
• W1542321037 cites W22857079 @default.
• W1542321037 cites W2406062456 @default.
• W1542321037 doi "https://doi.org/10.1046/j.0306-5251.2001.00031.x" @default.
• W1542321037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1874259" @default.
• W1542321037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11879258" @default.
• W1542321037 hasPublicationYear "2002" @default.
• W1542321037 type Work @default.
• W1542321037 sameAs 1542321037 @default.
• W1542321037 citedByCount "47" @default.
• W1542321037 countsByYear W15423210372012 @default.
• W1542321037 countsByYear W15423210372013 @default.
• W1542321037 countsByYear W15423210372014 @default.
• W1542321037 countsByYear W15423210372015 @default.
• W1542321037 countsByYear W15423210372016 @default.
• W1542321037 countsByYear W15423210372017 @default.
• W1542321037 countsByYear W15423210372018 @default.
• W1542321037 countsByYear W15423210372019 @default.
• W1542321037 countsByYear W15423210372020 @default.
• W1542321037 countsByYear W15423210372021 @default.
• W1542321037 countsByYear W15423210372022 @default.
• W1542321037 crossrefType "journal-article" @default.
• W1542321037 hasAuthorship W1542321037A5043906653 @default.
• W1542321037 hasAuthorship W1542321037A5056361445 @default.
• W1542321037 hasAuthorship W1542321037A5061029367 @default.
• W1542321037 hasAuthorship W1542321037A5083601745 @default.
• W1542321037 hasBestOaLocation W15423210371 @default.
• W1542321037 hasConcept C112705442 @default.
• W1542321037 hasConcept C126322002 @default.
• W1542321037 hasConcept C142724271 @default.
• W1542321037 hasConcept C185592680 @default.
• W1542321037 hasConcept C197934379 @default.
• W1542321037 hasConcept C204787440 @default.
• W1542321037 hasConcept C22979827 @default.
• W1542321037 hasConcept C27081682 @default.
• W1542321037 hasConcept C2776768464 @default.
• W1542321037 hasConcept C2777056448 @default.
• W1542321037 hasConcept C2777288759 @default.
• W1542321037 hasConcept C2778375690 @default.
• W1542321037 hasConcept C2778907293 @default.
• W1542321037 hasConcept C2779929075 @default.
• W1542321037 hasConcept C2780206985 @default.
• W1542321037 hasConcept C501593827 @default.
• W1542321037 hasConcept C55493867 @default.
• W1542321037 hasConcept C71924100 @default.
• W1542321037 hasConcept C98274493 @default.
• W1542321037 hasConceptScore W1542321037C112705442 @default.
• W1542321037 hasConceptScore W1542321037C126322002 @default.
• W1542321037 hasConceptScore W1542321037C142724271 @default.
• W1542321037 hasConceptScore W1542321037C185592680 @default.
• W1542321037 hasConceptScore W1542321037C197934379 @default.
• W1542321037 hasConceptScore W1542321037C204787440 @default.
• W1542321037 hasConceptScore W1542321037C22979827 @default.
• W1542321037 hasConceptScore W1542321037C27081682 @default.
• W1542321037 hasConceptScore W1542321037C2776768464 @default.
• W1542321037 hasConceptScore W1542321037C2777056448 @default.
• W1542321037 hasConceptScore W1542321037C2777288759 @default.
• W1542321037 hasConceptScore W1542321037C2778375690 @default.
• W1542321037 hasConceptScore W1542321037C2778907293 @default.
• W1542321037 hasConceptScore W1542321037C2779929075 @default.
• W1542321037 hasConceptScore W1542321037C2780206985 @default.
• W1542321037 hasConceptScore W1542321037C501593827 @default.
• W1542321037 hasConceptScore W1542321037C55493867 @default.
• W1542321037 hasConceptScore W1542321037C71924100 @default.
• W1542321037 hasConceptScore W1542321037C98274493 @default.
• W1542321037 hasIssue "s1" @default.
• W1542321037 hasLocation W15423210371 @default.
• W1542321037 hasLocation W15423210372 @default.
• W1542321037 hasLocation W15423210373 @default.
• W1542321037 hasLocation W15423210374 @default.
• W1542321037 hasOpenAccess W1542321037 @default.
• W1542321037 hasPrimaryLocation W15423210371 @default.
• W1542321037 hasRelatedWork W1971645794 @default.

• next